key: cord-0688145-2hk7icza
authors: Liu, Kunmeng; Zuo, Huali; Li, Guoguo; Yu, Hua; Hu, Yuanjia
title: Global Research on Artemisinin and its Derivatives: Perspectives from Patents
date: 2020-06-23
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.105048
sha: 9dfb295059e1d67d9f043089df7b08c1b2de8ea1
doc_id: 688145
cord_uid: 2hk7icza

BACKGROUND: The isolation of artemisinin in 1971 heralded the beginning of a new era in antimalarial drug therapy, and artemisinin-based combination therapies are currently the mainstay of malaria treatment worldwide. Artemisinin-related studies have been extensively and intensively executed in the last few decades. However, although many purely technological reviews have been completed in this field, studies on artemisinin from the perspective of patents are still very limited. In terms of the importance of patents for academic research and commercial development, this study aims to reveal the overall patent landscape of artemisinin in the temporal, spatial, and technological dimensions. This work may provide a useful reference for relevant decision-making by researchers, investors, and policymakers. METHODS: All available patent data relevant to artemisinin derivatives and artemisinin-based drug combinations developed for use in various therapeutic areas were collected from the Derwent Innovation database. Descriptive statistics and citation analyses were used to analyze the patent landscape. RESULTS: A total of 4594 patent documents and 1450 simple patent families from 1986 to 2019 were analyzed. A comprehensive patent landscape of artemisinin is presented from the aspects of time trends, filing countries, patent ownership, co-patents, technological categories, therapeutic areas, and citation networks and pathways. CONCLUSIONS: China and the United States are mainly responsible for the dramatic increase of artemisinin patents over the last three decades. From the point of view of patents, notable technological issues on artemisinin are chemical and biological synthesis, novel combinations, new formulations and administration routes, drug repositioning, and minimizing the resistance. Furthermore, a critical challenge lies in how to stimulate the industry to develop artemisinin-related drugs by government regulation and public-private partnership.

In 1971, the Chinese project 523 led by Tu Youyou (the first Nobel laureate in physiology or medicine in China) isolated a non-toxic extract of sweet wormwood plant. The extract is able to induce 100% parasite clearance in animal models of malaria (Plasmodium berghei and Plasmodium cynomolgi) [1, 2] . In 2006, the World Health Organization (WHO) recommended the adoption of artemisinin-based combination therapies (ACT) as first-line treatment options for the treatment of Plasmodium falciparum malaria [3] . During the last 50 years, chloroquine and sulfadoxine-pyrimethamine are the most widely recommended treatments for the potentially lethal malaria infection. However, an alternative is needed as they were no longer working effectively in most tropical countries. Resistance to these drugs also appeared in Asia and South America and spread to Africa. J o u r n a l P r e -p r o o f infectious effects, as well as antitumor, anti-inflammatory, anti-oxidant, antiangiogenesis, and apparent immunomodulatory effects [4] [5] [6] [7] . The anticancer activity of artemisinin derivatives has been extensively studied since being first reported in 1993 [8] . In addition, artemisinin and its derivatives are not only active against cancer cells, but also in human cytomegalovirus (HCMV) infections and other viral infections, as well as Schistosoma sp., Fasciola hepatica, Babesia sp., etc., as discovered in the last few years [2, [9] [10] [11] .

It is not surprising that a research on existing artemisinin-based molecules and the search for novel artemisinin compounds as potential therapeutic agents have been intensified in recent years, since artemisinin appears to possess a wide spectrum of activity and a relatively low toxicity profile. Such interest has led to abundant patents for artemisinin derivatives. As mentioned above, many technological analyses and reviews exist for artemisinin [1, [11] [12] [13] , but their patents have received little attention.

Patents in the life sciences are not only a crucial metric of innovation, but also a cornerstone for the commercialization of a new field in life science and healthcarerelated technologies. Moreover, patent analyses can be used to underpin important decision making and analyses by academics, industry, and governments.

To address this gap in knowledge, we reviewed global research on artemisinin and its derivatives from the perspective of patents by highlighting drug resistance and potential clinical benefits in non-malarial indications. This research is expected to show an overall patent landscape of artemisinin in the temporal, spatial, and technological dimensions, which may provide a reference for relevant decisionmaking by researchers, investors, and policymakers.

J o u r n a l P r e -p r o o f 5 The Derwent Innovation platform (a worldwide provider for enhanced patent documents) was used in this study to achieve a dataset of patents dealing with inventions related to artemisinin. We retrieved sample patents with publication date before August 31, 2019, accordingly to the rules of preferred reporting items for systematic reviews and meta-analyses (PRISMA), an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses [14] . In the data search for patents filed on artemisinin and its derivatives, the full names of artemisinin and its main derivatives, abbreviations, or synonyms were inputted into the patent topic (TS) field of the database. As for the dataset cleaning, a fundamental data normalization step was performed to clean duplicate records that had occurred due to abbreviations or misspelling. The unrelated patents were deleted in the document records after being checked manually. This study did not exclude patent applications that are still pending, in order to capture the latest progress in patenting activities due to rapid developments in recent years. Supplementary Figure 1 shows the detailed process of data inclusion, screening, and exclusion.

Each patent record consists of detailed information about a patent family, which includes the basic patent filed in the original country or office and subsequent equivalent patents on the same invention filed in different countries or offices. The patent analysis described below focuses on family-based patent information, including the basic patent number, patent publication year, assignees, title, abstract, international patent classification (IPC), application details of all the family members, and citation information. The items reported in this patent landscaping are according to the Reporting Items for Patent Landscapes (RIPL) checklist, which is the latest comprehensive standard for patent landscape reporting [15] .

J o u r n a l P r e -p r o o f Moreover, the study adopted a method of network analysis to review the artemisinin patents, which places emphasis not only on individual patents but also on the citation relationship between them. We constructed a series of patent citation networks, where nodes represent patents, and directed edges and arrows denote citation relationships and directions. Moreover, patents can be clustered together to form an independent network component, in which nodes have relatively frequent internal connections.

The structures and features within patent citation networks comprehensively indicate the patterns of technology flows and evolution. This study also used various descriptive approaches including heat maps, rose charts, word clouds, and chord diagrams to illustrate the patent indicators and associations between them.

In this study, the patent family was considered as the multiple patent applications of the same invention, filed in multiple patent offices within 12 months of the first filing In addition, a collaboration chord diagram was constructed to further investigate the collaboration patterns of patent assignees in artemisinin-related inventions ( Figure   2b ). In terms of patterns of partnerships between different organizational forms of assignees, they can be ranked by cooperation frequency as follows: C-U&R, C-C, U&R-U&R, U&R-I, C-I, and I-I. Of these, nearly one-third of the partnership collaborations are between C and U&R.

First, the assigned IPC categories of the patents indicate the technological areas that the inventions involve. Figure 3a depicts the change in the main IPC categories in 7digit codes by years. The most prevalent IPC category is A61K-031 (medicinal preparations containing active organic ingredients), which comprised 1438 patents. while the type of organic chemistry declined. Based on its production mechanism, artemisinin production was segmented as biosynthesis, chemical synthesis, and synthesis in engineered organisms. Patents that focus on the chemical synthesis of artemisinin account for a large number of the patents. Among artemisinin's main derivatives, it is expected that arteether-related patents will remain relatively stable each year with small amount of fluctuation over the years. A number of dihydroartemisinin, artesunate, and artemether-related patents experienced a series of fluctuations for two decades; however their overall tendency was upward.

Third, Figure 4 shows the ICD-11 (International Classification of Diseases 11th

Revision) of artemisinin patents. As regards the disease profile, the disease indication covered in the title, abstract, and claim of artemisinin patents were extracted and classified by ICD-11, which is the global standard for diagnostic health information.

The rose chart shown in Figure 4a In addition, artemisinin resistance is currently receiving much research attention. All patents related to drug resistance have been extracted (Supplementary Table 1 ). The continued use of oral artemisinin-based monotherapies is considered to be a major contributing factor to the development of resistance to artemisinin derivatives and ACTs are now recommended by the WHO. It can be seen that combining drugs (n=22 patent families) is the most commonly used technology. Combinations in which artemisinins are proposed for formulation with drugs used to treat co-morbidities that accompany malaria or independently occurring disease conditions aimed at minimizing the development of resistance but also at potentiation of activity. The patents of drug resistance reversal agents (n=6 patent families) indicate that J o u r n a l P r e -p r o o f 13 artemisinin has the potential to reverse drug resistance, which is of great importance considering that multidrug resistance is currently a major impediment to cancer treatment. Figure 5 shows the citation networks of artemisinin patents. In total, 1724 nodes and 2091 edges are plotted in Figure 5a . It is obvious that some patents are linked together more closely to form network clusters. To highlight the main technology clusters, we marked clusters with more than five patent members in different colors. The largest community, colored in blue, represents 9.18% of the nodes, the second, in orange, comprises 8.56% of nodes and the third, in green, 8.01%. The blue community includes patents with many big nodes, highlighting its importance to the network since it gathered the most cited patents.

Patents with a high out-degree, which means patents that are mainly cited by subsequent patents, represent the most basic and innovative technologies with high creativity, which others in the field are trying to imitate [16] . The most cited patents were labeled with patent numbers and are shown in Supplementary Table 2. These influential patents played critical roles in technological flows, such as patent US5578637, WO2009088404, US5225562, US6127405, and US6649647.

In order to reflect the evolution of network clusters, the 28 clusters with more than five patents were extracted and divided into three time periods, 1986-1999, 2000-2009, and 2010-2019, as illustrated in Figure 1a , based on the average year that the patents were granted within a specific cluster. Here, it can be seen that the most cited patents are mostly for the type of certain infectious or parasitic diseases. (Figure 5b 

Considering wide implications of patents in scientific, industrial and social dimensions, we further discuss global research on artemisinin and its derivatives in the three aspects. First, ongoing research on artemisinin and its derivatives has revealed its potential use in treating infectious and noninfectious diseases. Notably, it was reported that artemisinin derivatives exert their anticancer effects through distinctly different mechanisms than those of most existing anticancer agents [17] . Cancer cells are more prone to cytotoxic effect of artemisinins due to their high intracellular iron levels [18] .

Thus, introducing these derivatives into the anticancer armamentarium may address current critical challenges facing cancer chemotherapy, namely drug resistance and severe toxicity. In addition, with the emergence of infectious diseases such as SARS and MERS in recent years, chloroquine, the anti-malaria drug, has been used in experiments against these viruses and has good inhibitory effect with safety in vitro [19] [20] [21] . Artemisinin, which has antimalarial effect with an excellent safety index, may also has possibility and potential. Mateon announced that its COVID-19 directed antiviral screening program discovered that artemisinin is highly potent at inhibiting the ability of the COVID-19 causing virus to multiply [22] . In response to As is well-known, like "looking for needle in a haystack", drug discovery is a timeconsuming, costly, and risking work. New uses for old medications can significantly save time and cost with shortening R&D cycle, which can reduce the risk and improve the success rate of drug R&D. It is reported that this strategy can save about 40% of the R&D cost [23] and shorten the R&D pipeline by 3-12 years [24, 25] . In this sense, the development of new therapeutic areas related to artemisinin seems to be a In addition, drug combinations targeting multiple conditions can help to achieve medical compliance and work against drug resistance. Novel artemisinin combinations also have the advantage of improving therapeutic efficacy against resistant Plasmodium strains and greatly minimize disease transmission and resistance propagation [26, 27] . However, the beneficial effects of different combinations are neither obvious nor predictable. Consequently, the search for new artemisinin-based combinations is an ongoing process. As far as artemisinin-related new formulations and administration routes are concerned, sublingual, nasal or pulmonary delivery are potential orientation of administration route, while pills, lozenges or tablets, particulate form, liposomes and emulsions may be promising medicinal preparations.

Thus, the search for new artemisinin-based combinations with reduced dose, better amenability to combination with other drugs, novel derivatives with superior pharmacokinetic and toxicity profiles, large-scale synthesis in low cost, administration route demonstrating good bioavailability on rate and extent of absorption, as well as dosage forms that is active, stable and acceptable to the patient should be a continuous process.

For discussing industrial implications, it is necessary to make a brief review on the process of scientific discovery and commercial operation related to artemisinin. In the 1970s, Chinese scientists successfully extracted artemisinin. However, since there was no patent law in China at that time, no patent was applied for the invention, which was just summarized in a Chinese paper [28] . The powerful R&D institutions and pharmaceutical companies in France and Switzerland further conducted extensive research about artemisinin in the process of artificial synthesis, purification and preparation according to the technology disclosed in this paper, and applied for a large number of patents for technological improvement and related peripheral technologies (e.g., WO2015140709, WO2014078813, WO2011006143, and WO9202217). In most parts of the world, falciparum malaria has become resistant to conventional treatment [29] , and in 1990, WHO recommended that countries use the combination of drugs to fight malaria [30] . Under this background, Coartem® (Artemether-Lumefantrine Tablet) was originally developed based on patent CN1085527, which was applied by the Academy of Military Medical Sciences in China and further licensed to Novartis [30] [31] [32] [33] . Based on this patented drug, relevant generic drugs (corresponding companies) were developed, including Artefan® J o u r n a l P r e -p r o o f (Ajanta Pharma Ltd, India), and Lumart® (Cipla Ltd, India), and Laritem® (Ipca Laboratories Ltd, India) [34] .

In 2006, the further recommendation of WHO on ACTs made Novartis the biggest beneficiary and Novartis received a large number of orders from the WHO [35] [36] [37] .

Currently, as one of five ACTs [36, 38] recommended by the WHO, Coartem occupies about 85% of the public sector market of ACTs [39] . According to a report of Grand View Research [40] , global market size of ACTs is expected to reach nearly USD 

From the social angle, due to nonprofit nature of artemisinin products on malaria control, a critical challenge is how to keep a balance of pharmaceutical development between commercial motivation and social benefits.

In this study, only 36% artemisinin-related patents are owned by companies and the majority, 64% held by individuals, universities or research institutes. It is difficult only by academic institutions or persons to develop new drugs, while academic patents are not easy to be licensed out to the industry. In fact, the process of commercialization of scientific and research achievements is immature in many countries. Although there are many scientific research institutions, they do not have production conditions and skills to turn them into real commodities. In this regard, policy support is needed to promote technology transfer from academia to industry.

Co-patenting activities between firms and universities could exhibit a positive association with market value [45] , whereas co-patenting among firms has generally been considered disadvantageous to commercial performance and a second-best strategy that firms have preferred to avoid [46, 47] . Governments in the United States and the European Union are also trying to encourage partnerships between J o u r n a l P r e -p r o o f 20 universities, research centers, and companies to promote the movement of medical research from 'bench to bedside' [48] .

At present, 90% of the antimalarial market is supplied by public sector [41] , which is in the framework of international procurement agencies of Global Fund and WHO.

The WHO PQP helps to ensure that medicines provided by procurement agencies can meet acceptable standards of quality, safety and efficacy. Antimalarial drugs in the public sector must be recommended by "Guidelines for the Treatment of Malaria" and be prequalified by WHO. The products also should meet standard Good Manufacturing Practices (GMP) and Good Clinical Practice (GCP) by WHO. More importantly, WHO not only strictly controls the quality of the drugs, but also has a requirement of profit limited of less than 15% [41] . Obviously, enterprises may not produce such products if there is no enough profit.

As we mentioned before, before a drug is to be approved to market, it must be proved to be safe and effective through clinical trials at a quite high cost. The industry has to consider whether they can recoup the huge R&D expenditure by possible cheap price of artemisinin products in the market. In terms of the nature of public goods of medicines, worldwide governments try to keep a balance of pharmaceutical development between commercial motivation and social benefits by various means of drug registration and regulation, such as, accelerated approval, orphan drug designation, data exclusivity, patent term extension, price negotiations, reimbursement drug list and volume-based tendering. A notable example comes when China recently implemented a so-called "4+7" procurement initiative to impel market access of cheaper drugs [49] . The public is willing to choose drugs with better therapeutic effect and lower price. From the industrial angle, different social classes J o u r n a l P r e -p r o o f 21 have different affordability for medical expenses. Pharmaceutical companies may create diversified product portfolios by differential product positioning.

The intervention of public sector and favorable policy environment of motivating pharmaceutical companies are necessary, in terms of promising scientific and social value but relatively low commercial expectation of artemisinin. In a word, public needs, government regulation and industry diversification underpin cheap drugs like artemisinin, as long as they exactly may treat diseases.

However, this work has still some research limitations. Although a patent is a key innovation indicator, this patent-based analysis cannot reflect all R&D work on artemisinin and its derivatives. But, considering the existing numerous technological reviews on artemisinin, we believe that this kind of patent landscape analysis is still a necessary supplement to prior work. In addition, some recent inventions with potential creativity may be neglected in the citation-based analysis, because newer patents were often cited less obviously. We think it would be valuable to make a continuous observation that would allow updating of the patent landscape of artemisinin and its derivatives.

The number of artemisinin patents have been rising for the last 30 years. China and the United States are the most productive countries in terms of artemisinin patents and are important markets for artemisinin. Furthermore, in terms of patenting activity, the most attractive technological options on artemisinin include chemical and biological synthesis of new derivatives, novel combinations among known compounds, new formulations and administration routes, drug repositioning especially from infectious diseases to non-infectious ones, and minimizing the development of artemisininrelated resistance. Given scientific and social significance of above technological options, a critical challenge lies in how to motivate the industry to develop artemisinin-related drugs. Government regulation as well as public-private partnership have played and will continuously play an indispensable role in tomorrow's artemisinin products originated from today's patents.

This work was funded by the University of Macau by project MYRG2019-00011-ICMS.

The authors declared that they have no conflicts of interest to this work. a. Global citation network including all patents and their citation links. Bigger nodes represent highly cited patents. The node size was set according to its out-degree value, that is, the greater the out-degree, the larger the node size, and the more citations a given patent 

The Discovery of Artemisinin (Qinghaosu) and Gifts from Chinese Medicine

Use of Artesunate in Non-Malarial Indications

Artemisinin-Based Combination Treatment of Falciparum Malaria

Mechanistic Perspectives for 1, 2, 4-Trioxanes in Anti-Cancer Therapy

Antioxidant and Antimicrobial Effects of Artemisinin Extracts from Artemisia Annua L

The Antiviral Activities of Artemisinin and Artesunate

Efficacy of Praziquantel and Artemisinin Derivatives for the Treatment and Prevention of Human Schistosomiasis: A Systematic Review and Meta-Analysis, Parasites Vectors

Cytotoxicity of Artemisinin-Related Endoperoxides to Ehrlich Ascites Tumor Cells

Nobel Prize for Artemisinin Brings Phytotherapy into the Spotlight

Plasmodium Sensitivity to Artemisinins: Magic Bullets Hit Elusive Targets

Artemisinins: Their Growing Importance in Medicine

Artemisinin-a Gift from Traditional Chinese Medicine to the World (Nobel Lecture)

The Prisma Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations

The Reporting Items for Patent Landscapes Statement

A Penny for Your Quotes: Patent Citations and the Value of Innovations

Anticancer Properties of Distinct Antimalarial Drug Classes

Development of Artemisinin Compounds for Cancer Treatment

Screening an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Mers-Cov Pathogenesis and Antiviral Efficacy of Licensed Drugs in Human Monocyte-Derived Antigen-Presenting Cells

Targeting Endosomal Acidification by Chloroquine Analogs as a Promising Strategy for the Treatment of Emerging Viral Diseases

Mateon Expands Its Covid-19 Therapeutic Program to Include Artemisinin

Looking at the Opportunity of

Drug Repositioning: Identifying and Developing New Uses for Existing Drugs

New Uses for Old Drugs

A Temporizing Solution to "Artemisinin Resistance

Suboptimal Dosing Triggers Artemisinin Partner Drug Resistance

Collaborative research group on the structure of artemisinin, Artemisinin, a New Sesquiterpene Lactone

Why Is It Important to Combine Malaria Drugs?

What Does Patent Bring: Review on the Development of Antimalarial Drugs of Artemisinin

KPC: Participated in the Research and Development of Antimalarial Drugs for More Than 50 Years, and Will Promote the International Development of Artemisinin

The Protection of Intellectual Property Rights of Medical Scientific Research Achievements from the History and Current Situation of Artemisinin Patent

The Mother of Artemisinin: Tu Youyou, Chinese Nobel Laureate in Physiology or Medicine in 2015

Assessing the Quality of

Drugs from Gabonese Pharmacies Using the Minilab®: A Field Study

WHO, WHO Briefing on Malaria Treatment Guidelines and Artemisinin Monotherapies

Novartis Announced the Quantity of Artemisinin APIs Purchased [38] WHO

Coartem Has Entered Maturity Period

Breaking through the

Chinese Nobel Laureate 'Cautiously Optimistic' About Progress Towards Lupus Treatment

KPC Pharma Soars after Saying Chinese Nobel Laureate's New Drug Is in Clinical Trials

Lists of Medicines/Finished Pharmaceutical Products

Co-Ownership of Intellectual Property: Exploring the Value-Appropriation and Value-Creation Implications of Co-Patenting with Different Partners

Technological Activities and Their Impact on the Financial Performance of the Firm: Exploitation and Exploration within and between Firms

Joint Patenting Amongst Companies-Exploring the Effects of Inter-Firm R&D Partnering and Experience

Pharmaceutical Public-Private Partnerships: Moving from the Bench to the Bedside

Drug Procurement

The authors gratefully acknowledge Xiangjun Kong and Ling Hou from the University of Macau for valuable comments that helped in improving this work.

All data included in this study are available upon request by contact with the corresponding author.J o u r n a l P r e -p r o o f